ReviewFrontiers in oncology2026
Radiotherapy as a partner for immunotherapy in pancreatic cancer: current landscape and future directions.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) continues to rise in incidence and remains one of the deadliest solid tumors due to its insidious onset and extremely poor overall survival. Current therapeutic options-surgery, chemotherapy, and radiotherapy-offer limited benefit for most patients, largely because of the tumor's dense stromal architecture, profoundly immunosuppressive microenvironment, and inherent resistance to conventional treatments. In recent years, advances in immune checkpoint inhibitors (ICIs), cancer vaccines, oncolytic viruses, and adoptive cell therapies have driven steady progress in the field of PDAC immunotherapy. At the same time, multimodal strategies that combine immunotherapy with radiotherapy, targeted agents, or chemotherapy have begun to show promising synergistic activity. This review summarizes the recent developments in both single-agent and combination immunotherapeutic approaches for PDAC, and highlights the key challenges and future directions for improving treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.